Literature DB >> 87679

Improvement of chronic congestive heart-failure by oral captopril.

G A Turini, H R Brunner, M Gribic, B Waeber, H Gavras.   

Abstract

Catopril, an inhibitor of angiotensin converting enzyme, was given orally during cardiac catheterisation to 6 normotensive patients with refractory congestive heart-failure. 60--180 minutes after administration of 25 mg captopril, arterial pressure fell by 25%, cardiac index rose by 38%, and left-ventricular pressure and right-atrial pressure fell by 25% and 40% respectively. Plasma-renin activity rose while plasma noradrenaline and aldosterone fell. These data suggest that, in the short term, captopril can reduce both preload and afterload, and improve cardiac function, in refractory congestive heart-failure.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 87679     DOI: 10.1016/s0140-6736(79)91897-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  34 in total

1.  The renin-angiotensin system and the heart: a historical review.

Authors:  S J Cleland; J L Reid
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

2.  Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  A A Ajayi; N Hockings; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

3.  Does captopril lower blood pressure in anephric patients?

Authors:  A J Man in 't Veld; G J Wenting; M A Schalekamp
Journal:  Br Med J       Date:  1979-11-03

Review 4.  How ACE inhibitors transformed the renin-angiotensin system.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

5.  Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects.

Authors:  D B Brunner; G Desponds; J Biollaz; I Keller; F Ferber; H Gavras; H R Brunner; J L Schelling
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

6.  Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.

Authors:  H Urata; K D Boehm; A Philip; A Kinoshita; J Gabrovsek; F M Bumpus; A Husain
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

Review 7.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

8.  Steady-state pharmacokinetics and pharmacodynamics of benazeprilat in spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats.

Authors:  S LeRoy; B Berner
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

9.  Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects.

Authors:  A J Man in 't Veld; I M Schicht; F H Derkx; J H de Bruyn; M A Schalekamp
Journal:  Br Med J       Date:  1980-02-02

10.  RHC 3659: a new orally active angiotensin converting enzyme inhibitor in normal volunteers.

Authors:  M Burnier; G A Turini; H R Brunner; M Porchet; D Kruithof; R A Vukovich; H Gavras
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.